In the latest market close, Organon (OGN) reached $18.58, with a -1.33% movement compared to the previous day. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Prior to today's trading, shares of the pharmaceutical company had lost 14.72% over the past month. This has lagged the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21% in that time. Analysts and investors alike will be keeping a close ey ...

In the latest market close, Organon (OGN) reached $19.17, with a +0.74% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.4% for the day. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%. The pharmaceutical company's stock has dropped by 15.31% in the past month, falling short of the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the ...

Company Performance - Organon (OGN) closed at $20.47, with a daily gain of +0.89%, outperforming the S&P 500's gain of 0.54% [1] - Over the past month, Organon's shares increased by 0.35%, lagging behind the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with a forecasted EPS of $0.97, reflecting an 11.49% increase from the same quarter last year [2] - Revenue is projected at $1.56 billion, indicating a 2.44% rise from the equivalent quarter last year [2] Annual Estimates - For the annual period, earnings are expected to be $4.33 per share, with revenue anticipated at $6.34 billion, representing increases of +4.59% and +1.28% respectively from the previous year [3] Analyst Projections - Recent shifts in analyst projections should be monitored, as positive revisions indicate optimism regarding the company's business and profitability [4] Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 4 (Sell), with the consensus EPS estimate remaining unchanged over the last 30 days [6] - The Forward P/E ratio for Organon is 4.68, significantly lower than the industry average of 22.16, and the PEG ratio stands at 0.85 compared to the industry average of 1.57 [7] Industry Context - The Medical Services industry, to which Organon belongs, has a Zacks Industry Rank of 173, placing it in the bottom 32% of over 250 industries [8]

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this pharmaceutical company have returned +1%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 1.2%. The key question now is: What could be the stock's future direction? Altho ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this pharmaceutical company have returned +0.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term? Alt ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned -2.5% over the past month versus the Zacks S&P 500 composite's -3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 0.7% over this period. Now the key question is: Where could the stock be headed in the near term? Although media re ...

Organon (OGN) reported $1.61 billion in revenue for the quarter ended June 2024, representing a year-overyear decline of 0.1%. EPS of $1.12 for the same period compares to $1.31 a year ago. The reported revenue represents a surprise of -1.13% over the Zacks Consensus Estimate of $1.63 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +5.66%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

Organon & Co. (NYSE:OGN) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Jennifer Halchak - Head of IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Umer Raffat - Evercore ISI Ethan Brown - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Operator Thank you for standing-by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the ...

Organon (OGN) came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.97 per share when it actually produced earnings of $1.22, delivering a surprise of 25.77%. Over the last four quarters, the co ...

Organon & Co. (OGN) is scheduled to report second-quarter 2024 results on Aug 6, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of $1.22 surpassed the Zacks Consensus Estimate by 25.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed once, delivering an earnings surprise of 13.6%, on average. Let's check out the factors that have shaped OGN's performance prior to this announcement. Factor ...